|
|
|
|
|
05.06.25 - 17:48
|
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the first quarter of 2026, with the objective of extending the product label to this age group....
|
|
|
|
|
|
|
|
|
|
|
|
|
12.05.25 - 14:01
|
Valneva: Aktie trotzt negativen News (Der Aktionaer)
|
|
|
Die Aktie von Valneva kann sich auch zum Wochenstart gut behaupten. Trotz negativer News zum Chikungunya-Impfstoff IXCHIQ ist das Papier im Tagesverlauf auf der Handelsplattform Tradegate ins Plus gedreht. Bereits in der vergangenen Woche hatte die Europäische Arzneimittelagentur EMA die Verwendung des Impfstoffs für Personen über 65 Jahre ausgesetzt....
|
|
|
12.05.25 - 11:33
|
Valneva Aktie: EMA setzt Ixchiq für Senioren aus - Kursziel gesenkt (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Valneva-Aktienanalyse von Guggenheim Securities:
Aktuelle Bewertung
Guggenheim-Analyst Vamil Divan hat das Kursziel für Valneva SE (ISIN: FR0004056851, WKN: A0MVJZ, Ticker-Symbol: AYJ, Euronext Paris-Symbol: VLA) von 15 USD auf 14 USD reduziert, hält aber am "buy"-Rating fest. [mehr]...
|
|
|
12.05.25 - 07:03
|
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States (GlobeNewswire EN)
|
|
|
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause in the use of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® in elderly individuals while ongoing investigations into reported serious adverse events (SAEs) are completed. This update follows an earlier recommendation from the U.S. Advisory Committee on Immunization Practices (ACIP) to include a precaution related to the use of IXCHIQ® in persons aged 65 and over and a similar decision by the European Medicines Agency (EMA) to temporarily suspend the use of the vaccine for individuals over 65 years old pending investigation....
|
|
|
|
|
|
|
|
|
07.05.25 - 17:48
|
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly (GlobeNewswire EN)
|
|
|
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ® for people from 12 to 64 years of age....
|
|
|
|
|
07.05.25 - 07:03
|
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva)....
|
|
|
26.04.25 - 19:12
|
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities (GlobeNewswire EN)
|
|
|
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government's call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed cases since the beginning of 20252....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
